Halozyme Therapeutics Inc (HALO)

[rod5247]

Pfizer taking second target to clinic. Even though dated earlier, showing up on clinicaltrials.gov today.

Not yet recruiting Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase

Conditions:
Hypercholesterolemia; Healthy

Interventions:
Biological: Cohort 1: bococizumab 150 mg + rHuPH20; Biological: Cohort 2: bococizumab 300 mg; Biological: Cohort 3: bococizumab 300 mg + rHuPH20; Biological: Cohort 4: bococizumab 300 mg + rHuPH20; Biological: Cohort 5: bococizumab 450 mg + rHuPH20

Phase:
Phase 1

Sponsor/Collaborators:
Pfizer; Halozyme Therapeutics

Study Start:
February 2016

Primary Completion:
July 2016

First Received:
January 6, 2016

Last Updated:
January 25, 2016